Drug intelligence / Profile preview

Oftaial Plus

Development stage: Unknown
Lead developer: Alfa Intes
Administration: Ophthalmic

Overview

Oftaial Plus is a hypotonic medical device ophthalmic solution developed by Alfa Intes for the treatment of dry eye syndrome and lacrimal dysfunction. The formulation contains sodium hyaluronate (0.4%) and taurine (0.5%), along with essential salts such as magnesium, potassium, and sodium chloride. Sodium hyaluronate acts as a high-molecular-weight lubricant and humectant that stabilizes the tear film and protects the corneal epithelium from environmental stressors, contact lens wear, and digital screen use. Taurine, an amino acid naturally present in tear fluid, serves as an osmoprotectant, supporting cell survival and ocular surface health under hyperosmotic conditions. The product is preservative-free and available in both multi-dose and single-dose formats.

Brand names: Oftaial Plus

Beyond the preview

Go deeper on Oftaial Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oftaial Plus.

Explore the full profile